"Complement C3a" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The smaller fragment generated from the cleavage of complement C3 by C3 CONVERTASE. C3a, a 77-amino acid peptide, is a mediator of local inflammatory process. It induces smooth MUSCLE CONTRACTION, and HISTAMINE RELEASE from MAST CELLS and LEUKOCYTES. C3a is considered an anaphylatoxin along with COMPLEMENT C4A; COMPLEMENT C5A; and COMPLEMENT C5A, DES-ARGININE.
| Descriptor ID |
D015926
|
| MeSH Number(s) |
D12.776.124.486.274.024.250 D12.776.124.486.274.250.250
|
| Concept/Terms |
Complement C3a- Complement C3a
- C3a, Complement
- Complement 3a
- Complement Component 3a
- Component 3a, Complement
- C3a Complement
- Complement, C3a
|
Below are MeSH descriptors whose meaning is more general than "Complement C3a".
Below are MeSH descriptors whose meaning is more specific than "Complement C3a".
This graph shows the total number of publications written about "Complement C3a" by people in this website by year, and whether "Complement C3a" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Complement C3a" by people in Profiles.
-
Safety evaluation of intravenously administered mono-thioated aptamer against E-selectin in mice. Toxicol Appl Pharmacol. 2015 Aug 15; 287(1):86-92.
-
Immune cell-derived C3a and C5a costimulate human T cell alloimmunity. Am J Transplant. 2013 Oct; 13(10):2530-9.
-
C3a enhances nerve growth factor-induced NFAT activation and chemokine production in a human mast cell line, HMC-1. J Immunol. 2004 Jun 01; 172(11):6961-8.
-
[A new case of bronchospasm under extracorporeal circulation]. Ann Fr Anesth Reanim. 1986; 5(2):157-9.